Abstract:Abstract Purpose of study: Residues P/K/D/N/H undergo enzymatic hydroxylations essential for proteins that, like collagens, fibrillins, collectins, and hypoxia-inducible factors, co-determine cancer outcome. Despite disparate protein substrates, these enzymes follow identical catalysis by activating inhaled O2 for hydroxylation - the HAG mechanism, formulated in a 1983 thesis. It details catalysis at subatomic resolution, classifies all possible inhibitors, identifies the first selective inhibitor of collagen and collectin biosynthesis, and defines the numerous 2-oxoacid utilizing dioxygenases (2OUDs). The HAG mechanism is considered ‘seminal’ for drug development (https://pubmed.ncbi.nlm.nih.gov/7857312/). mechanism2OUDs occur in clusters. This predicts HAG inhibitors to act across polygenic hydroxylation-dependent protein families relevant in cancer. Single-drug multi-targeted inhibition is a paradigm for anticancer drug discovery (e.g. AlimtaTM [https://ascopubs.org/doi/pdf/10.1200/JCO.1999.17.10.3009]). We tested multi-targeted 2OUD suppression with an FDA-approved medicine, deferiprone (DEF), that per HAG mechanism blocks 2OUD cofactors (2-oxoacid, ascorbate). Hypothesis: HAG mechanism blockade in multiple 2OUD-reliant pathways triggers a cascade of aftereffects; in cancer cells, this HAG sequence is lethal and immunogenic. Methods: Culture/metabolic labeling/RNA-seq/flow cytometry of models for high grade serous ovarian cancer (KURAMOCHI), uterine serous cancer (ARK1), and cancer-associated fibroblasts (MRC5). Results: In a dose-dependent manner at clinical concentrations, DEF inhibited [3H]Pro/[3H]Lys hydroxylation, not incorporation; and caused intracellular accumulation of hydroxylation-deficient collagens (COL1A1, -3A1, -6A1, -11A2, -18A1), fibrillins (FBN1), collectins (C1QA,-B, -C), and HIFs (EPAS1), exceeding controls up to 10-fold. After 96 hrs, accumulation reversed in MRC5, remained elevated in KURAMOCHI, and rose further in ARK1. Activation of the ablative unfolded protein response (UPR), via enhanced DDIT3, TRIB3, BAK1, PMAIP1, HRK expression, coincided with a >80% decline in cancer cell count. In MRC5, DEF downregulated apoptosis markers (cleaved PARP-1, active caspase 3), but upregulated both over controls in KURAMOCHI and ARK1, which also showed enhanced expression of pyroptosis markers (caspase 1, IL-18, gasdermins). Conclusions: DEF reactivity reveals HAG mechanism inhibition at multiple 2OUDs that hydroxylate P/K/D/N residues in cancer-relevant proteins. The ensuing HAG sequence captures the secondary effects, e.g. HIF2α-driven synthesis of underhydroxylated, therefore UPR-retained COL/FBN, triggering apoptotic cancer cell death that, due to C1q deficiency, must proceed without autoimmunity. Citation Format: Spencer M. Goering, Sukhwinder Singh, Axel-Rainer Hanauske, Bernadette M. Cracchiolo, Isabel W. Cracchiolo, Angela A. Sandev, Hartmut M. Hanauske-Abel. Integrating protein hydroxylase inhibition into cancer therapeutics: From orbital interactions at hydroxylase active sites to misfolded protein-driven cancer cell death and immunogenic cancer cell apoptosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1591.

Abstract 4812: Inhibition of Smurf2 E3 ubiquitin ligase by heclin and its analogues enhances HIF-1α expression and transcriptional activity in normoxia or hypoxia

Abstract 120: HIF-1α regulation by Smurf2-mediated protein degradation in a VHL-independent manner

Smurf1 polyubiquitinates on K285/K282 of the kinases Mst1/2 to attenuate their tumor-suppressor functions.

Targeting the SMURF2-HIF1α axis: a new frontier in cancer therapy

Smurf1 Polyubiquitinates on K285/K282 of the Kinases Mst1/2 to Attenuate Their Tumor-Suppressor Functions

Abstract 378: PHD3 dependent stabilization of β3-adrenoceptor induces HIF-1αactivation in Ewing sarcoma

Smurf1 Ubiquitin Ligase Targets Kruppel-like Factor KLF2 for Ubiquitination and Degradation in Human Lung Cancer H1299 Cells.

Smurf2, an E3 Ubiquitin Ligase, Interacts with PDE4B and Attenuates Liver Fibrosis Through Mir-132 Mediated CTGF Inhibition

Abstract 3980: Hypoxia-induced Microrna-424 Targets CUL2 to Stabilize HIF-α Isoforms and Promotes Angiogenesis

Abstract 376: Targeting the convergence on HIF-1α of CDK4/6 and MAPK pathway: Implications for enhanced anticancer strategies

Oxia Inducible Factor 1α and Hypoxia Inducible Factor 2α Distinct and Functionally Overlapping Roles in R L Squamous Cell Carcinoma

Abstract B7: Activation of PPARα Suppresses HIF-1α Signaling in Human Cancer Cells.

Abstract 119: Stabilization of Hypoxia-Inducible Factor-1Α by the Human Rhomboid Family-1 Gene Product RHBDF1

Abstract 1591: Integrating protein hydroxylase inhibition into cancer therapeutics: From orbital interactions at hydroxylase active sites to misfolded protein-driven cancer cell death and immunogenic cancer cell apoptosis

Downregulation of Smurf2 ubiquitin ligase in pancreatic cancer cells reversed TGF-β-induced tumor formation

Abstract 391: Role of NRF2 in HIF-2α-mediated cancer stem cell phenotype

Hydrogen Sulfide Inhibits the Translational Expression of Hypoxia‐inducible Factor‐1α

SMURF2 prevents detrimental changes to chromatin, protecting human dermal fibroblasts from chromosomal instability and tumorigenesis

SMURF1, a Promoter of Tumor Cell Progression?

Abstract 610: ClpP-dependent and -independent activation of HRI kinase by small molecules

The Ubiquitination Ligase SMURF2 Reduces Aerobic Glycolysis and Colorectal Cancer Cell Proliferation by Promoting ChREBP Ubiquitination and Degradation.